$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

Scienture Revenue Triples After REZENOPY Naloxone Launch

Scienture Holdings reported third-quarter 2026 results on Monday, November 16, 2026. Revenue reached $1.25 million, up about 265 percent from the second quarter and 113 percent from a year earlier. REZENOPY, the company's 10 mg naloxone nasal spray launched in August, produced about $925,000 of that total in its first wholesale shipments.

TML Health DeskNov 17, 11:50 AM ET · 2 min read

Edited and fact-checked by Stephen Sprague

A naloxone hydrochloride package (archive). Scienture's REZENOPY is a 10 mg naloxone nasal spray, and its first wholesale shipments produced about $925,000 of net product revenue in the third quarter. Photo: Intropin, via Wikimedia Commons.
Summary

Scienture's two products now sell, and the losses still run near five dollars for every dollar of revenue. The company's own target is breakeven operating income in 2027, and the clinic channel it signed in September is where the next revenue has to come from.

Tap a passage. React to the part that matters.

In Commack, New York, on Monday, Scienture Holdings filed the first quarter in its history built on two selling drugs.

Revenue for the third quarter ended September 30, 2026 came to $1.25 million. That's up about 265 percent from $343,639 in the second quarter and about 113 percent from $590,050 in the same quarter of 2025. The company had previewed about $1.22 million on October 13, and the reported figure cleared it.

REZENOPY did most of the work. The spray is naloxone hydrochloride at 10 mg, which Scienture calls the highest-dose FDA-approved naloxone nasal spray sold in the United States. It reached the market in August 2026, and initial wholesale shipments generated about $925,000 of net product revenue in the quarter.

For a family that keeps a spray in a kitchen drawer, the dose is the practical point. A stronger spray is built for overdoses driven by potent synthetic opioids, where a standard dose may not restore breathing on the first attempt.

Arbli, the company's first product, generated about $330,000 in the quarter and $730,000 across the first nine months. It's a liquid form of losartan, the blood pressure drug, and it's the first FDA-approved oral liquid version that doesn't require compounding. Wholesale unit sales rose 74 percent from the second quarter.

Gross profit rose about 77.5 percent to $1.02 million, and the gross margin reached about 81.3 percent. Scienture says the margin reflects REZENOPY joining the revenue mix. Nine-month revenue rose about 176 percent to $1.65 million, with gross profit of $1.41 million.

The loss column is still much larger than the revenue column. The third-quarter net loss was about $6.0 million, against about $3.6 million a year earlier, and the operating loss was about $5.7 million. The quarter carried about $0.8 million of FDA fees and about $0.8 million as a licensing milestone for REZENOPY, plus higher research spending.

Distribution is the part of the release with a street address on it. In September, Scienture signed an exclusive sales, marketing and distribution agreement aimed at opioid treatment program clinics and addiction treatment centers, a network of about 2,000 facilities. After the quarter ended, the company shipped its first REZENOPY orders through that direct channel.

Arbli's institutional foothold is narrower and specific. Scienture says the drug holds formulary placements at more than ten leading U.S. pediatric hospitals and academic medical centers, and that it is expanding coverage through CMS and commercial payors.

Cash, cash equivalents and restricted cash stood at about $7.8 million on September 30, up from about $6.7 million at the end of 2025. Management says the current sales run rate puts the business in position to reach breakeven operating income and profitability in 2027. That's a company projection, not a result, and it depends on the two products continuing to grow at something like this pace.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.